ConductScience.org, home

Paper27141007

Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.

Iasonos A and 2 others. Clin Cancer Res, 2016. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Papers, record 27141007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27141007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.14
iCite
Revised in PubMed
2018-11-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Iasonos AAlexia
2Chapman PBPaul B
3Satagopan JMJaya M

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BiomarkersMajor topic
Humans
Mutation
Proportional Hazards Models
Risk Assessment
Risk Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
R01 CA137420NCI NIH HHSUnited StatesR01CA137420PubMed and NIHNIH RePORTER
R01 CA197402NCI NIH HHSUnited StatesR01CA197402PubMed and NIHNIH RePORTER
UL1 TR000457NCATS NIH HHSUnited StatesUL1TR000457PubMed and NIHNIH RePORTER

Download CSV of grants

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115273082Hazard ratio in clinical trials.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/15273082PubMed
226027431Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med2015https://conductscience.org/library/papers/26027431PubMed
34027319Testing for qualitative interactions between treatment effects and patient subsets.Biometrics1985https://conductscience.org/library/papers/4027319PubMed
418316791Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.J Clin Oncol2008https://conductscience.org/library/papers/18316791PubMed
518946061K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med2008https://conductscience.org/library/papers/18946061PubMed
620010207The hazards of hazard ratios.Epidemiology2010https://conductscience.org/library/papers/20010207PubMed
721102529Statistical interaction in human genetics: how should we model it if we are looking for biological interaction?Nat Rev Genet2011https://conductscience.org/library/papers/21102529PubMed
821107323Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Nature2010https://conductscience.org/library/papers/21107323PubMed
921150212The meaning of interaction.Hum Hered2010https://conductscience.org/library/papers/21150212PubMed
1021337591Personalized estimates of breast cancer risk in clinical practice and public health.Stat Med2011https://conductscience.org/library/papers/21337591PubMed
1121705679Risk factor modification and projections of absolute breast cancer risk.J Natl Cancer Inst2011https://conductscience.org/library/papers/21705679PubMed
1221705680The numbers game: the risky business of projecting risk.J Natl Cancer Inst2011https://conductscience.org/library/papers/21705680PubMed
1321931068Helping patients decide: ten steps to better risk communication.J Natl Cancer Inst2011https://conductscience.org/library/papers/21931068PubMed
1422658127Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012https://conductscience.org/library/papers/22658127PubMed
1523134356Progression of RAS-mutant leukemia during RAF inhibitor treatment.N Engl J Med2012https://conductscience.org/library/papers/23134356PubMed
1624982461Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.J Clin Oncol2014https://conductscience.org/library/papers/24982461PubMed
1725452452Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.J Clin Oncol2015https://conductscience.org/library/papers/25452452PubMed
186366135Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.J Clin Oncol1983https://conductscience.org/library/papers/6366135PubMed

Download CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
39707607Genetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival.Int J Cancer2025https://conductscience.org/library/papers/39707607PubMed
36038907lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.J Transl Med2022https://conductscience.org/library/papers/36038907PubMed
34750392Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nat Commun2021https://conductscience.org/library/papers/34750392PubMed
28934243Time to publication of oncology trials and why some trials are never published.PLoS One2017https://conductscience.org/library/papers/28934243PubMed
28258415Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping.Ann Surg Oncol2017https://conductscience.org/library/papers/28258415PubMed
28254404Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.Contemp Clin Trials2017https://conductscience.org/library/papers/28254404PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27141007

GET https://conductscience.org/api/papers/v1/27141007/authors